Hematopoietic Stem Cell Transplantation for Multiple Myeloma: Guidelines from the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant 2015 Jul;21(7):1155-66
Date
03/15/2015Pubmed ID
25769794DOI
10.1016/j.bbmt.2015.03.002Scopus ID
2-s2.0-84930577739 (requires institutional sign-in at Scopus site) 98 CitationsAbstract
Therapeutic strategies for multiple myeloma (MM) have changed dramatically over the past decade. Thus, the role of hematopoietic stem cell transplantation (HCT) must be considered in the context of this evolution. In this evidence-based review, we have critically analyzed the data from the most recent clinical trials to better understand how to incorporate HCT and when HCT is indicated. We have provided our recommendations based on strength of evidence with the knowledge that ongoing clinical trials make this a dynamic field. Within this document, we discuss the decision to proceed with autologous HCT, factors to consider before proceeding to HCT, the role of tandem autologous HCT, post-HCT maintenance therapy, and the role of allogeneic HCT for patients with MM.
Author List
Shah N, Callander N, Ganguly S, Gul Z, Hamadani M, Costa L, Sengsayadeth S, Abidi M, Hari P, Mohty M, Chen YB, Koreth J, Landau H, Lazarus H, Leather H, Majhail N, Nath R, Osman K, Perales MA, Schriber J, Shaughnessy P, Vesole D, Vij R, Wingard J, Giralt S, Savani BN, American Society for Blood and Marrow TransplantationAuthors
Mehdi H. Hamadani MD Professor in the Medicine department at Medical College of WisconsinParameswaran Hari MD Adjunct Professor in the Medicine department at Medical College of Wisconsin
MESH terms used to index this publication - Major topics in bold
Age FactorsChromosome Aberrations
Disease Management
Evidence-Based Medicine
Gamma Rays
Hematopoietic Stem Cell Transplantation
Humans
Multiple Myeloma
Myeloablative Agonists
Randomized Controlled Trials as Topic
Time Factors
Transplantation Conditioning
Transplantation, Autologous
Transplantation, Homologous
